Utility of post-therapy brain surveillance imaging in the detection of XXXX relapse.

@entity1 @entity5 @entity149 @entity2592 @entity1892 @entity1499
BACKGROUND: The optimal follow-up strategy for @entity149 ( @entity149 ) @entity1 after first-line therapy is unclear. The goal of this study is to determine the utility of planned brain surveillance imaging in the detection of relapse in a retrospective cohort of @entity149 @entity1 . METHODS: @entity1 were consecutive @entity149 cases treated in Leon @entity5 Centre, Lyon, France, from 1985 to 2011. Histology was diffuse large @entity1892 in 94%. @entity1 were treated by @entity1499 (92%) and @entity2592 (63%) based-chemotherapy followed by radiotherapy for 108 @entity1 (51%). Clinical records were reviewed for details at relapse and relationship to planned imaging. The imaging follow-up strategy was performed according to each treating physicians. RESULTS: Among 209 @entity149 @entity1 , 127 complete response @entity1 entered in post-treatment observation and 63 (50%) subsequently relapsed. Among the 125 evaluable @entity1 , the majority of relapses (N  =  49, 80%) was asymptomatic and identified before the planned brain imaging. Surveillance imaging detected relapses before symptoms in 12 @entity1 who entered in post-therapy observation (10%). The median number of brain imaging during the follow-up was 7 (0-13). A total of 819 MRI/CT-scan were performed leading to the detection of 12 asymptomatic relapses. The one year OS rates were 41% and 58% for symptomatic and non-symptomatic relapses, respectively (P  =  0.21). CONCLUSION: The majority of @entity149 relapses occurred outside planned follow-up with no difference in @entity1 outcome between symptomatic and asymptomatic relapses. The role of brain imaging for the detection of relapses in the follow-up of @entity149 @entity1 remains to be clarified.
